Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

NCT05827549 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoid Leukemia

Interventions

DRUG: Reinduction(4weeks)
DRUG: Cosolodation 1st(3weeks)
DRUG: Consolidation 2nd(3weeks)
DRUG: Blinatumomab 1st(High Risk Group)_4 Weeks
DRUG: Blinatumomab 2nd (High Risk Group)_4 Weeks
DRUG: Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks
DRUG: Blinatumomab-Salvage 2nd (Very High Risk Group)_4 Weeks
DRUG: Intensification course
DRUG: Maintenance(12 Weeks/Cycle)
PROCEDURE: Stem Cell Transplantation

Sponsor

Ho Joon Im

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]